Rezolute (RZLT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Sep 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RZLT SEC filings page.
This page shows Rezolute, Inc. (RZLT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rezolute remains a research-funded loss-maker: spending stays high while its asset base and financing support contract.
The key mismatch is that FY2026 net loss was$77.6M while operating cash flow was-$64.6M : accounting losses were more negative than cash movement, so the two measures did not move one-for-one. That cushion did not prevent contraction: assets fell35.7% from FY2025 while financing cash flow fell97.9% , indicating a shrinking resource base alongside much less new funding.
FY2026 research and development remained the larger expense at
Liabilities were
Financial Health Signals
We do not publish a peer-relative financial health score for Rezolute, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Rezolute, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Rezolute, Inc. reported a net loss of $77.6M while operations used $64.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Rezolute, Inc. reported a net loss of $20.5M in Q4 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Rezolute, Inc. earned -$0.20 per diluted share (EPS) in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
Rezolute, Inc. held $10.6M in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Not reported for Q4 2026.
Margins & Returns
Rezolute, Inc.'s quarterly ROE was -20.4% in Q4 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 6.5 percentage points.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Capital Allocation
Rezolute, Inc. invested $14.9M in research and development in Q4 2026. This represents a decrease of 28.6% from the same quarter a year earlier. Against the prior quarter it is up 30.5%.
Not reported for Q4 2026.
Not reported for Q4 2026.
RZLT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $14.9M-28.6% | $11.4M-25.3% | $14.3M+13.6% | $13.1M+3.1% | $20.9M+9.3% | $15.3M+23.2% | $12.6M+4.9% | $12.8M+4.4% |
| SG&A Expenses | $6.7M+33.8% | $6.0M+25.6% | $9.9M+121.7% | $6.7M+59.3% | $5.0M+24.3% | $4.7M+24.3% | $4.5M+41.1% | $4.2M+13.2% |
| Operating Income | -$21.6Mn/m | -$17.4Mn/m | -$24.2Mn/m | -$19.8Mn/m | -$25.9Mn/m | -$20.0Mn/m | -$17.1Mn/m | -$16.9Mn/m |
| EBITDA | N/A | -$17.4Mn/m | -$24.2Mn/m | -$19.8Mn/m | N/A | -$20.0Mn/m | -$17.1Mn/m | -$16.9Mn/m |
| Net Income | -$20.5M | -$16.2Mn/m | -$22.8Mn/m | -$18.1Mn/m | N/A | -$18.9Mn/m | -$15.7Mn/m | -$15.4Mn/m |
| EPS (Basic) | -$0.20n/m | -$0.16n/m | -$0.22n/m | -$0.18n/m | -$0.26n/m | -$0.27 | -$0.22n/m | -$0.22n/m |
| EPS (Diluted) | -$0.20n/m | -$0.16n/m | -$0.22n/m | -$0.18n/m | -$0.26n/m | -$0.27 | -$0.22n/m | -$0.22n/m |
| Diluted Shares (Avg) | N/A | 104M+48.6% | 104M+48.3% | 103M+48.3% | N/A | 70M | 70M+36.0% | 70M+35.6% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
RZLT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $112.8M-35.7% | $125.5M+32.4% | $138.6M+23.8% | $158.7M+28.6% | $175.5M+32.2% | $94.7M+8.0% | $112.0M+9.6% | $123.4M+9.2% |
| Current Assets | $110.5M-35.4% | $122.0M+37.5% | $135.1M+36.9% | $154.7M+40.4% | $171.1M+33.0% | $88.7M+7.9% | $98.7M+2.7% | $110.2M+7.3% |
| Cash & Equivalents | $10.6M-88.7% | $11.2M-23.0% | $11.9M+33.7% | $9.1M-13.1% | $94.1M+33.7% | $14.6M+146.1% | $8.9M-28.6% | $10.5M+30.0% |
| Short-Term Investments | $97.2M+31.8% | $109.0M+50.8% | $121.0M+38.1% | $143.1M+46.3% | $73.8M+30.6% | $72.3M-2.4% | $87.6M+9.4% | $97.8M+7.9% |
| Long-Term Investments | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $1.5M-3.8% | $8.8M+161.8% | $9.6M+17.3% |
| Total Liabilities | $12.2M-9.0% | $8.6M-29.1% | $10.6M-14.4% | $11.5M+15.3% | $13.4M+13.9% | $12.2M-27.9% | $12.4M+19.2% | $10.0M+5.7% |
| Current Liabilities | $11.4M-4.1% | $7.7M-26.8% | $9.5M-10.2% | $10.2M+27.8% | $11.9M+24.0% | $10.5M+51.3% | $10.6M+32.5% | $8.0M+11.1% |
| Non-Current Liabilities | $744K-48.7% | $921K-43.9% | $1.1M-39.1% | $1.3M-35.1% | $1.5M-31.8% | $1.6M-83.4% | $1.8M-25.0% | $2.0M-11.5% |
| Total Equity | $100.7M-37.9% | $116.8M+41.5% | $128.0M+28.5% | $147.2M+29.7% | $162.1M+34.0% | $82.6M+16.5% | $99.6M+8.6% | $113.4M+9.5% |
| Retained Earnings | -$481.4Mn/m | -$461.0Mn/m | -$444.8Mn/m | -$422.0Mn/m | -$403.9Mn/m | -$379.5Mn/m | -$360.6Mn/m | -$344.8Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RZLT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.1Mn/m | -$13.7Mn/m | -$20.3Mn/m | -$17.4Mn/m | -$22.0Mn/m | -$17.4Mn/m | -$13.7Mn/m | -$16.0Mn/m |
| Depreciation & Amortization | $8K0.0% | $8K+14.3% | $7K-12.5% | $8K0.0% | $8K+14.3% | $7K-22.2% | $8K-20.0% | $8K-20.0% |
| Stock-Based Compensation | N/A | $4.4M+132.0% | $3.4M+136.1% | $2.5M+80.8% | N/A | $1.9M+0.1% | $1.4M-21.3% | $1.4M-24.3% |
| Investing Cash Flow | $12.3M+3454.3% | $12.3M-46.7% | $22.8M+98.9% | -$68.5Mn/m | $346K-98.2% | $23.1M+165.9% | $11.5M-35.4% | -$49.4M-1996.0% |
| Financing Cash Flow | $227K-99.8% | $747K+7370.0% | $356K-45.8% | $911K-83.4% | $101.2M+59.7% | $10Kn/m | $657K | $5.5M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
RZLT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -20.4% | -13.8%+9.1pp | -17.8%-2.0pp | -12.3%+1.2pp | N/A | -22.9%+1.2pp | -15.8%-0.6pp | -13.6%+0.5pp |
| Return on Assets | -18.2% | -12.9%+7.1pp | -16.4%-2.4pp | -11.4%+1.0pp | N/A | -20.0%-0.5pp | -14.0%-0.4pp | -12.5%+0.4pp |
| Current Ratio | 9.68-4.7x | 15.84+7.4x | 14.18+4.9x | 15.15+1.4x | 14.37+1.0x | 8.43-3.4x | 9.30-2.7x | 13.79-0.5x |
| Liabilities-to-Equity | 0.120.0x | 0.07-0.1x | 0.080.0x | 0.080.0x | 0.080.0x | 0.15-0.1x | 0.120.0x | 0.090.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Rezolute, Inc. RZLT | FY2026 | N/A | -$77.6M | N/A | $375.3M | — |
| Altimmune, Inc. ALT | FY2025 | $41K | -$88.1M | N/A | $392.9M | — |
| Avalo Therapeutics, Inc. AVTX | FY2025 | $59K | -$78.3M | N/A | $392.6M | — |
| Zura Bio Limited ZURA | FY2025 | N/A | -$68.7M | N/A | $379.5M | — |
| Relmada Therapeutics, Inc. RLMD | FY2025 | N/A | -$57.4M | N/A | $409.6M | — |
| Capricor Therapeutics Inc CAPR | FY2025 | $0 | -$105.0M | N/A | $420.9M | — |
Where Rezolute, Inc. Ranks
Frequently Asked Questions
No, Rezolute, Inc. (RZLT) reported a net loss of $77.6M in fiscal year 2026.
Rezolute, Inc. (RZLT) had EBITDA of -$82.9M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
Rezolute, Inc. (RZLT) has a return on equity of -77.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
Rezolute, Inc. (RZLT) recorded an outflow of $64.6M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
Rezolute, Inc. (RZLT) had $112.8M in total assets as of fiscal year 2026, including both current and long-term assets.
Rezolute, Inc. (RZLT) invested $53.8M in research and development during fiscal year 2026.
Rezolute, Inc. (RZLT) had a current ratio of 9.68 as of fiscal year 2026, which is generally considered healthy.
Rezolute, Inc. (RZLT) had a liabilities-to-equity ratio of 0.12 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
Rezolute, Inc. (RZLT) had a return on assets of -68.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Rezolute, Inc. (RZLT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $375.3M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Rezolute, Inc. (RZLT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $375.3M as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2026, Rezolute, Inc. (RZLT) held $107.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $64.6M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Rezolute, Inc. (RZLT) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Rezolute, Inc. (RZLT) reported a net loss of $77.6M while operations used $64.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.